122 related articles for article (PubMed ID: 9924698)
1. An in vivo model to study immunotoxin-induced vascular leak in human tissue.
Baluna R; Vitetta ES
J Immunother; 1999 Jan; 22(1):41-7. PubMed ID: 9924698
[TBL] [Abstract][Full Text] [Related]
2. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice.
Smallshaw JE; Ghetie V; Rizo J; Fulmer JR; Trahan LL; Ghetie MA; Vitetta ES
Nat Biotechnol; 2003 Apr; 21(4):387-91. PubMed ID: 12627168
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.
Baluna R; Rizo J; Gordon BE; Ghetie V; Vitetta ES
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3957-62. PubMed ID: 10097145
[TBL] [Abstract][Full Text] [Related]
4. An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers.
Lindstrom AL; Erlandsen SL; Kersey JH; Pennell CA
Blood; 1997 Sep; 90(6):2323-34. PubMed ID: 9310483
[TBL] [Abstract][Full Text] [Related]
5. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.
Soler-RodrÃguez AM; Ghetie MA; Oppenheimer-Marks N; Uhr JW; Vitetta ES
Exp Cell Res; 1993 Jun; 206(2):227-34. PubMed ID: 8388800
[TBL] [Abstract][Full Text] [Related]
6. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
Liu XY; Pop LM; Schindler J; Vitetta ES
MAbs; 2012; 4(1):57-68. PubMed ID: 22327430
[TBL] [Abstract][Full Text] [Related]
7. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
Siegall CB; Liggitt D; Chace D; Tepper MA; Fell HP
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9514-8. PubMed ID: 7937798
[TBL] [Abstract][Full Text] [Related]
8. In vitro studies of ricin A-chain-induced vascular leak syndrome.
Lindstrom AL; Pennell CA
Methods Mol Biol; 2001; 166():125-35. PubMed ID: 11217363
[No Abstract] [Full Text] [Related]
9. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage.
Baluna R; Coleman E; Jones C; Ghetie V; Vitetta ES
Exp Cell Res; 2000 Aug; 258(2):417-24. PubMed ID: 10896793
[TBL] [Abstract][Full Text] [Related]
10. Taming ricin toxin.
Kreitman RJ
Nat Biotechnol; 2003 Apr; 21(4):372-4. PubMed ID: 12665820
[No Abstract] [Full Text] [Related]
11. Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins.
Baluna R; Sausville EA; Stone MJ; Stetler-Stevenson MA; Uhr JW; Vitetta ES
Clin Cancer Res; 1996 Oct; 2(10):1705-12. PubMed ID: 9816120
[TBL] [Abstract][Full Text] [Related]
12. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.
Schindler J; Sausville E; Messmann R; Uhr JW; Vitetta ES
Clin Cancer Res; 2001 Feb; 7(2):255-8. PubMed ID: 11234876
[TBL] [Abstract][Full Text] [Related]
13. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
Frankel AE; Laver JH; Willingham MC; Burns LJ; Kersey JH; Vallera DA
Leuk Lymphoma; 1997 Jul; 26(3-4):287-98. PubMed ID: 9322891
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome.
Wang H; Song S; Kou G; Li B; Zhang D; Hou S; Qian W; Dai J; Tian L; Zhao J; Guo Y
Cancer Immunol Immunother; 2007 Nov; 56(11):1775-83. PubMed ID: 17431617
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
18. Immunotoxins and vascular leak syndrome.
Vitetta ES
Cancer J; 2000 May; 6 Suppl 3():S218-24. PubMed ID: 10874491
[No Abstract] [Full Text] [Related]
19. Toxicologic evaluations of an immunotoxin, H65-RTA.
Kung AH; Cavagnaro JA; Makin A; White MA; Kong KN
Fundam Appl Toxicol; 1995 Jun; 26(1):75-84. PubMed ID: 7657064
[TBL] [Abstract][Full Text] [Related]
20. Vascular leak syndrome: a side effect of immunotherapy.
Baluna R; Vitetta ES
Immunopharmacology; 1997 Oct; 37(2-3):117-32. PubMed ID: 9403331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
